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Dear Editor, 
Gestational diabetes mellitus (GDM) is a vital medical 
complication of pregnancy in which glucose intolerance is first 
detected or develops during gestation. GDM is associated with 
adverse maternal and neonatal outcomes, and contemporarily, 
several clinical trials have tested their incidence in antenatal 
vitamin D receiving GDM patients. Considering their clinical 
significance, these trials' findings pertaining to the above 
outcomes require cautious interpretation, in terms of the risk of 
bias due to missingness. Any such bias in randomized 
controlled trials (RCT) can contaminate the results of a meta-
analysis that extracts data from these RCTs. Best known to me, 
perhaps, no review article has explored the perinatal outcomes 
in these trials in the context of missingness. Therefore, this 
letter attempts to draw on it to highlight its importance and 
briefs the contemporarily available techniques to handle it in a 
meta-analysis setting. In this letter, missingness refers to the 
incomplete outcome data of participants who were not observed 
until the end of the trial, but not the available outcome data the 
trialists excluded from statistical analysis.  
     The assessment of the risk of bias in RCTs varies depending 
on the assessed outcome types (dichotomous or continuous). In 
the RCTs reporting dichotomous outcomes, their ratio of 
missingness to the number of events of interest helps compare 
their risk of bias. The risk of bias increases as this ratio 
becomes bigger [1]. Using this method, I piloted the 
missingness associated plausible risk of bias between two 
relevant RCTs as examples [2,3]. I compared some of the 
maternal (preterm delivery, pre-eclampsia, polyhydramnios, 
macrosomia (>4000 gm), and cesarean section) and neonatal 
(hospitalization, hyperbilirubinemia, and hypoglycemia) 
outcomes reported in both the trials.  Although these trials had 
few missing data, given their small sample sizes and clinical 
importance, it seems apropos to include here [2,3]. For the 
cesarean section, and hyperbilirubinemia and hospitalization of 
newborns, the risk of bias due to missingness was reasonably 
low as these ratios had relatively lower values and were  
 
identical among the trials (Table 1). However, for the remaining 
outcomes, juxtaposed to Jamilian et al. [3] study, these ratios 
were higher in that by Asemi et al. [2], suggesting a higher risk 
of bias in the later. For instance, the ratios for newborn 
hypoglycemia in these studies were 0.30 and 2.50, respectively. 
The above can also be determined by the risk of occurrence of a 
binomial outcome. If two hypothetical trials had an identical 
proportion of missing data, the risk of bias in the results would 
have been higher in the trial with a lower risk of events [1].   
     Likewise, the chances of bias can be judged for continuous 
outcomes, for example; in systematic review articles intending 
to judge RCTs that tested the changes in gestational weight or 
body mass index in prenatal vitamin D receiving GDM patients 
[4]. The influence of missingness of such outcomes increases 
with the proportion of missing data in these trials [1].  
     Besides the above considerations, the risk of bias assessment 
attributable to missingness requires an exploration of their 
reasons and balance between the compared intervention groups. 
When these are identical, the trials are likely to be at a lower 
risk of bias [1]. However, even if the missingness is balanced 
between the intervention groups, bias may creep in if its reasons 
are dissimilar [1]. For example, in one of the RCTs discoursed 
above [2], although the missingness was almost balanced 
among the treatment arms, the causes were not identical. 
     In addition to the risk of bias assessment, meta-analytic 
methods like the available case analysis (ACA) and imputation 
case analysis are also valuable to explore the impact of missing 
outcome data. It is based on the assumption that participants are 
missing at random (MAR), which is conditional on other 
variables included in the meta-analysis, but not dependent on 
the outcome [5,6]. However, MAR assumption can’t be 
validated during meta-analysis when the reasons for attrition are 
not known, and a sensitivity analysis like best-case and worst-
case scenario and pattern mixture models might be required [5]. 
Pattern mixture models quantify the degree of departure from 
MAR by informative missingness odds ratio for binomial 
outcomes [6].  
     Overall, this discourse implies that the evidence from RCTs 
on dichotomous maternal and neonatal outcomes in prenatal 
vitamin D supplemented GDM mothers should be judged in 
conjunction with the above-stated factors of incomplete 
outcome data. Nevertheless, through this letter, perhaps I have 
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only scratched the surface of the context; therefore, a systematic 
review may be more appropriate for a detailed exploration of 
the issue.  
Table 1 Incomplete outcome data to event ratio for maternal 
and neonatal outcomes of two trials 
 
 
Outcome 
Author+, year 
Jamilian et al., 
2019# [3] 
Asemi et al., 
2015## [2] 
Event 
(n) 
Ratio 
(missing
/event) 
Event 
(n) 
Ratio  
(missing 
/event) 
M
a
te
r
n
a
l 
o
u
tc
o
m
e
s 
Preterm delivery 2 1.50 1 5 
Preeclampsia  10 0.30 1 5 
Polyhydramnios  8 0.38 4 1.25 
Macrosomia (>4000gm) 8 0.38 4 1.25 
Cesarean section 29 0.10 26 0.19 
N
e
o
n
a
ta
l 
o
u
tc
o
m
e
s 
Newborn 
hyperbilirubinemia 
17 0.18 20 0.25 
Newborn 
hospitalization 
15 0.20 20 0.25 
Newborn hypoglycemia 10 0.30 2 2.50 
+First author’s last name, # no. of missing = 3, ## no. of missing = 5 
 
Abbreviations 
GDM: Gestational diabetes mellitus; RCT: Randomized Controlled 
Trials; ACA: Available Case Analysis; MAR: Missing at Random  
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